[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"proton-pump-inhibitors\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:proton-pump-inhibitors":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,46,70,102],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100526033","deprescribing-inappropriate-proton-pump-inhibitors-100526033",false,"NCT06129474","Deprescribing Inappropriate Proton Pump Inhibitors","DepRescribing inapprOpriate Proton Pump InhibiTors - the DROPIT Trial: a Cluster Randomized Controlled Trial in Primary Care Setting","DROPIT","Inclusion Criteria:\n\n1. Patient of a participating GP.\n2. Age: minimum 18 years old.\n3. Daily PPI intake for minimum 8 weeks.\n4. PPI in one of the following doses:\n\n   * minimum 40mg\u002Fday pantoprazole;\n   * minimum 40mg\u002Fday omeprazole;\n   * more than 30mg\u002Fday lansoprazole;\n   * more than 30mg\u002Fday dexlansoprazole;\n   * more than 20mg\u002Fday esomeprazole;\n   * more than 20mg\u002Fday rabeprazole.\n5. Sufficient knowledge of German language to understand the trial and follow-up according to GP assessment.\n\nExclusion Criteria:\n\n1. Limited life expectancy according to GP judgement (patients with terminal disease and a life expectancy of less than 12 months.\n2. Unable to provide informed consent.\n3. PPI in an appropriate dose (see Appendix Table A1) and with an established indication for long-term PPI, such as:\n\n   * History of bleeding ulcer.\n   * Peptic ulcer due to cause other than NSAID or H. Pylori.\n   * Barrett's oesophagus.\n   * Severe erosive reflux disease (Los Angeles grade C\u002FD).\n   * GERD with symptoms or complications (oesophageal ulcer, peptic stricture).\n   * Other indications (i.e., Zollinger-Ellison-Syndrome, PPI-sensitive eosinophilic esophagitis, chronic pancreatitis with steatorrhea refractory to enzyme replacement therapy, idiopathic pulmonary fibrosis.)\n4. Two or more of the following medications, or one of the following medications and one or more of the mentioned risk factors mentioned below.\n\nMedications (any dose):\n\n* Daily use of non-steroidal anti-inflammatory drug (NSAID) for more than 7 days.\n* Antiplatelet therapy.\n* Additional antiplatelet therapy (e.g., ticagrelor or similar).\n* Anticoagulant(s).\n* Systemic steroid(s) for more than 1 month.\n\nRisk factors:\n\n* History of gastrointestinal ulcer.\n* Age of 75 years and older.\n* Selective serotonin reuptake inhibitor (SSRI) or serotonin and norepinephrine reuptake inhibitor (SNRI) use.\n* Severe concomitant disease with increased risk of GI bleeding according to the GP's assessment (e.g., severe liver disease, neoplasia, nicotine or alcohol abuse).","ALL","18 Years",{"count":20,"type":21},400,"ESTIMATED","INTERVENTIONAL",[24],"NA","The DROPIT Trial is an interventional, open-labelled, cluster-randomized controlled trial conducted in the Swiss primary care setting. It aims to evaluate an intervention to guide the deprescribing of inappropriate proton-pump inhibitors (PPIs). Therefore, the trial investigates whether the study intervention leads to the deprescribing of inappropriate PPI prescription while ensuring noninferiority safety, in comparison to usual care. Additionally, the trail aims to investigate the intervention's impact on other clinical aspects, as well as addressing features of the implementation of the intervention and its cost-effectiveness.",[27,28,29],"Inappropriate Prescribing","Reflux Disease","Proton Pump Inhibitors",[31,32],"Deprescribing","Proton pump inhibitors","RECRUITING","2026-05-11",{"date":36,"type":37},"2026-05-14","ACTUAL",{"date":39,"type":37},"2024-10-01",{"date":41,"type":21},"2027-12-31",{"name":43,"class":44},"University of Bern","OTHER",2,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":55,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":69},"100483987","phase-4-ppi-infusion-versus-oral-acid-pump-inhibitors-for-bleeding-peptic-ulcers-100483987","NCT05582174","PPI Infusion Versus Oral Acid Pump Inhibitors for Bleeding Peptic Ulcers","A Comparison Between a High Dose PPI Intravenous Infusion and Oral Acid Pump Inhibitors After Endoscopic Haemostasis to Bleeding Peptic Ulcers","Inclusion Criteria:\n\n* \\- Patients aged ≥18 years who had undergone oesophagogastroduodenoscopy (OGD) for sign and symptoms of aneamia or upper GI bleeding including haematochezia, melaena or haematemesis, and found to a non-variceal upper GI cause of bleeding (peptic ulcers, dieulafoy's lesions, Mallory Weiss tear with active bleeding or major stigmata of haemorrhage\n* Major stigmata of recent haemorrhage includes peptic ulcers with spurting or oozing bleeding (Forrest classification Ia and Ib, respectively) ,with a nonbleeding visible vessel (Forrest classification IIa) or an adherent clot (Forrest classification IIb). For peptic ulcers with an adherent clot (Forrest classification IIb), the clot would be lifted (by irrigation using syringe boluses or water pump device, or manipulation with a snare or alligator etc.) and ulcer base examined to look for underlying vessels. Once the clot is removed, any identified underlying active bleeding or nonbleeding visible vessel should receive endoscopic haemostasis\n* Patients who had undergone endoscopic hemostatic treatment (a combination of hemoclipping therapy or contact thermocoagulation using multipolar\u002Fbipolar electrocautery probes or haemostatic forceps, with or without preinjection of diluted epinephrine. Endoscopic haemostasis is defined as no evidence of bleeding after irrigation and 3 minutes of observation\n\nExclusion Criteria:\n\n* No consent\n* Patients under the age of 18\n* Patients who were pregnant or in lactation\n* Hypersensitivity to PPI or Vonoprazan or any component of the formulation\n* Patients who were found to have tumour bleeding, oesophageal varices as the cause of the NVGIB\n* NVGIB due to post therapeutic endoscopic treatment such as gastric polypectomy, endoscopic mucosal resection, endoscopic submucosal dissection etc.",{"count":54,"type":21},594,[56],"PHASE4","Vonoprazan (VPZ), an oral potassium-competitive acid blocker (P-CAB) has emerged as an alternative potent acid-suppressant.It has a faster onset of action in 1 day (3-5 days in PPI), and is more stable in acidic condition than PPI. While many studies compared Vonoprazan against PPI in the treatment of reflux oesophagitis, H. Pylori eradication, and gastric ulcers; thus far, there is a paucity of data on use of Vonoprazan on bleeding peptic ulcers.\n\nWe perform a multicenter randomized controlled trial (RCT) to compare the efficacy of oral Vonoprazan against standard high dose PPI therapy in bleeding peptic ulcers that had received successful endoscopic haemostasis We hypothesize that in patients with bleeding peptic ulcers, the use of acid pump inhibitors Vonoprazan would not be inferior to standard treatment of a bolus plus high dose PPI intravenous infusion at preventing recurrent bleeding after endoscopic haemostasis.",[59,29],"Upper GI Bleeding","2026-03-16",{"date":62,"type":37},"2026-03-18",{"date":64,"type":37},"2023-05-18",{"date":66,"type":21},"2028-07-03",{"name":68,"class":44},"Chinese University of Hong Kong",8,{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":17,"minAge":78,"maxAge":79,"enrollmentInfo":80,"targetDuration":4,"studyType":82,"phases":4,"briefSummary":83,"conditions":84,"keywords":87,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":101},"100595759","intestinal-microbiota-after-ppi-treatment-100595759","NCT07036627","Intestinal Microbiota After PPI Treatment","Evaluation of the Intestinal Microbiota in Pediatric Patients Treated With Proton Pump Inhibitors: A Prospective Longitudinal Study","PPI","Inclusion Criteria:\n\n* Male or female children and adolescents aged between 6 months and 17 years at the time of enrollment.\n* Clinical indication for proton pump inhibitor therapy, including but not limited to gastroesophageal reflux disease, esophagitis, or functional dyspepsia.\n* Willingness and ability of the child and their caregivers to comply with all study procedures, including collection of fecal samples at scheduled time points.\n* Written informed consent obtained from a parent or legal guardian; assent obtained from the child, when age-appropriate, in accordance with local regulations and ethical standards.\n\nExclusion Criteria:\n\n* Use of systemic antibiotics, antifungals, or probiotics within 30 days prior to the start of the study or during the observation period.\n* Incomplete or improperly handled stool sample collection, or failure to adhere to protocol-defined sampling windows.\n* Known diagnosis of primary immunodeficiency, inflammatory bowel disease (e.g., Crohn's disease or ulcerative colitis), or celiac disease.\n* Any condition that, in the opinion of the investigator, may interfere with the integrity of the study or pose additional risks to the participant.","6 Months","17 Years",{"count":81,"type":21},100,"OBSERVATIONAL","This clinical study aims to investigate the effects of short-term treatment with proton pump inhibitors (PPIs) on the gut microbiota of pediatric patients. PPIs are among the most frequently prescribed medications in children and adolescents for the management of acid-related disorders, such as gastroesophageal reflux disease (GERD). However, emerging evidence suggests that these medications may have unintended consequences on the delicate ecosystem of beneficial microorganisms residing in the human gastrointestinal tract.\n\nThe intestinal microbiota plays a pivotal role in modulating immune responses, supporting nutrient metabolism, and maintaining the integrity of the gut barrier. Disruption of this microbial balance-known as dysbiosis-has been associated with several health conditions, including infections, allergies, obesity, and chronic inflammation. In adults, long-term PPI use has been linked to microbiota alterations, but data in the pediatric population remain limited and inconclusive.\n\nTo address this gap, our prospective longitudinal study will recruit pediatric patients prescribed PPI therapy for clinical indications. Stool samples will be collected at four time points: prior to PPI administration, during treatment, and at two follow-up stages post-cessation. Using 16S rRNA gene sequencing, we will profile changes in microbial diversity and abundance over time.\n\nThe results will offer insight into whether short-term PPI exposure in children leads to significant, lasting changes in gut microbiota composition or diversity. Such information may ultimately inform prescribing practices, support personalized therapeutic strategies, and help mitigate potential risks associated with microbiota disruption during childhood-a critical period for microbial and immune system development.",[29,85,86],"Human Gastrointestinal Tract","Gastroesophageal Reflux Disease",[76,88,89,90],"GERD","microbiota","gastroesophageal reflux","NOT_YET_RECRUITING","2025-06-25",{"date":94,"type":37},"2025-06-29",{"date":96,"type":21},"2025-07-06",{"date":98,"type":21},"2027-02-01",{"name":100,"class":44},"University of Bari",1,{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":4,"eligibilityCriteria":108,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":109,"targetDuration":4,"studyType":22,"phases":111,"briefSummary":112,"conditions":113,"keywords":115,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":101},"100582059","rak-pride-optimizing-proton-pump-inhibitor-use-through-education-and-intervention-100582059","NCT06858384","RAK-PRIDE: Optimizing Proton Pump Inhibitor Use Through Education and Intervention","From Awareness to Action: Transforming Proton Pump Inhibitor Use in Ras Al Khaimah Through Education and Intervention: the RAK -PRIDE Study","Inclusion Criteria:\n\nPhysicians will be eligible to participate if:\n\n* They are prescribing PPIs in outpatient department of the study sites\n* They have patients with potentially inappropriate PPI prescriptions\n\nPatients will be eligible to participate if:\n\n* They are ≥18 years\n* They are presenting to out-patient departments of the study sites\n* They have prescriptions of potentially inappropriate PPIs\n* Their treating physicians are included in the study\n\nExclusion Criteria:\n\nPhysicians will be excluded if:\n\n• They are involved in any other prescribing trial\n\nPatients will be excluded if:\n\n* They are unable to give informed consent, as judged by their physicians\n* They have definitive indications for PPI use",{"count":110,"type":21},479,[24],"The goal of this study is to determine if a pharmacist-led educational intervention can reduce the inappropriate use of proton pump inhibitors (PPIs) among adult patients (≥18 years) with potentially inappropriate PPI prescriptions in Ras Al Khaimah.\n\nThe main questions it aims to answer are:\n\n* Can a pharmacist-led education program reduce unnecessary PPI use?\n* Does the intervention improve patients' quality of life and reduce healthcare costs? Researchers will compare the intervention group (receiving pharmacist-led education and materials) to the usual care group to see if the intervention reduces PPI use and improves patient outcomes.\n\nParticipants will:\n\n* Receive educational materials from pharmacists, including a patient educational brochure, PPI patient decision aid, PPI deprescribing pamphlet, and PPI patient action plan.\n* Physicians involved will also receive a pharmaceutical intervention, which includes a physician educational brochure, PPI evidence-based deprescribing guideline, PPI deprescribing algorithm, and whiteboard videos on PPI deprescribing.\n* Patients will be followed up for 6 months to monitor changes in PPI use, symptoms, and quality of life.",[29,31,114],"Inappropriate Use",[116,117,31,118,119,120],"proton pump inhibitors","peptic ulcer disease","pharmacist-led educational intervention","inappropriate use","RAK - PRIDE","2025-03-08",{"date":123,"type":37},"2025-03-12",{"date":125,"type":21},"2025-03",{"date":127,"type":21},"2026-02",{"name":129,"class":44},"RAK Medical and Health Sciences University"]